The purpose of this study is to find out if the Oncotype DX® Recurrence Score (a diagnostic breast cancer test that looks at the activity of 21 different genes in breast tumor tissue. The tissue measures the chances of breast cancer returning) can help decide whether patients should receive chemotherapy or not. This study is being done in patients with lower Recurrence Scores (25 or less).
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1- 3 Positive Nodes, Hormone Receptor Positive and Her-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: RxPONDER: A Clinical
961-11Principal Investigator: Conducted at:
Long Beach Medical CenterCurrently enrolling additional patients:
18 & olderGender: